Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)
Rhea-AI Summary
Jaguar Health (NASDAQ: JAGX) family company Napo announced acceptance of two late-breaking abstracts at ESPGHAN for liquid oral crofelemer treating pediatric intestinal failure (IF) from microvillus inclusion disease (MVID) and short bowel syndrome (SBS).
Company reports crofelemer was well tolerated, associated with reductions in parenteral support (PS) and gains in weight/height in treated pediatric patients; orphan drug designations exist in the US and EU and a pediatric randomized MVID trial completed enrollment with an NDA planned mid-2027.
Positive
- Two late-breaking abstracts accepted for ESPGHAN presentation
- Orphan drug designations for MVID and SBS in US and EU
- Completed enrollment of pediatric MVID randomized trial; NDA planned mid-2027
- Reported reductions in parenteral support needs in treated pediatric IF patients
- Crofelemer described as well tolerated with patient weight and height gains
Negative
- Crofelemer currently used in approximately 4% of prevalent MVID patients
- Clinical evidence comes from investigator-initiated and ongoing trials, not yet regulatory approval
- Parenteral support remains required for patients; reductions reported but not elimination of PS
News Market Reaction – JAGX
In the Apr 24 session, JAGX declined 1.67%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 20 | Special meeting results | Positive | -0.8% | All five stockholder proposals approved at the April 2026 special meeting. |
| Apr 13 | AI program support | Positive | +5.7% | Plans to use AI platforms to enhance crofelemer IF development and commercialization. |
| Apr 09 | Earnings webcast notice | Neutral | -2.6% | Announcement of investor webcast to discuss Q4 2025 financials and updates. |
| Apr 08 | CID trial milestone | Positive | -2.6% | Completion of Canalevia-CA1 effectiveness study for chemotherapy-induced diarrhea in dogs. |
| Apr 07 | 2025 financial results | Negative | -0.1% | Reported higher operating losses and net loss alongside modest revenue trends. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often met with flat-to-negative reactions, even on seemingly constructive updates.
Over the last month, Jaguar Health reported 2025 financials with higher losses, completed an effectiveness trial for canine CID, highlighted AI support for crofelemer IF programs, and secured stockholder approval for all proposals at an April 20, 2026 special meeting. Price reactions ranged from modest declines around regulatory and financial updates to a 5.69% gain on AI-enabled IF program news. Today’s pediatric IF crofelemer data and ESPGHAN abstracts continue the rare-disease intestinal failure development narrative.
Key Terms
orphan drug designations regulatory
nda regulatory
intestinal failure medical
microvillus inclusion disease medical
short bowel syndrome medical
total parenteral nutrition medical
parenteral support medical
double-blind placebo-controlled trial medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Intestinal Failure (IF) occurs in patients with an ultrarare congenital enteropathy due to microvillus inclusion disease (MVID) and/or short bowel syndrome (SBS)
Jaguar has received orphan drug designations for MVID & SBS in the US and EU
Jaguar has also completed enrollment of pediatric MVID patients in an ongoing randomized clinical trial with plans for an NDA filing in mid-2027
SAN FRANCISCO, CA / ACCESS Newswire / April 24, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced the acceptance of two late breaking abstracts for the treatment of pediatric IF from MVID and SBS at the 58th Annual Meeting of ESPGHAN. These pediatric IF patients are receiving liquid oral crofelemer as an investigational drug under two separate investigator-initiated trials. One infant MVID IF patient is being treated with crofelemer as adjunctive therapy to parenteral support for more than 6 months and other pediatric patients with IF due to MVID and/or SBS received crofelemer adjunctive therapy for over 1 year together with reduced amounts of parenteral support (PS).
"We are pleased with these results for the safety and effectiveness of liquid oral crofelemer as adjunctive therapy to PS pediatric IF patients on life-sustaining PS. MVID is a congenital enteropathy and has a lethal natural history if not treated with life-sustaining and lifelong total parenteral nutrition (TPN) with or without supplemental intravenous fluids. MVID is estimated to have a prevalence of approximately 200 patients, and to the best of our knowledge, crofelemer is being used to treat approximately
Lisa Conte, the company's founder and CEO, said that "Crofelemer continues to have an impressive safety profile while demonstrating disease progression modification for the fragile pediatric IF patient population. The company has received interest and support from the parents of these IF patients, which has been heartening and inspirational."
Jaguar's family company, Napo Therapeutics S.P.A., is continuing to enroll adult patients with IF due to SBS using the same formulation of crofelemer. This randomized double-blind placebo-controlled trial is being conducted at multiple sites in Germany and Italy. An investigational study in adult SBS-IF patients is also being partially supported by the company in the US.
Intestinal failure is a debilitating condition that often requires patients to receive life-sustaining fluids, electrolytes and nutrients through intravenous administration, which consists of total parenteral nutrition (TPN) with supplemental intravenous fluids, which together constitute PS. Many intestinal failure patients require PS up to 7 days a week, and sometimes for 20 hours or more per day. While crucial for intestinal failure patients, PS is associated with serious toxicities to patients, including life-threatening infections, metabolic complications, liver and kidney function problems, reduction in normal growth parameters, cognitive functioning impacts among others.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including MVID and short bowel syndrome.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire